Navigation Links
Spartan Bioscience Names Charudutt Shah as Director of Business Development
Date:8/26/2014

Ottawa, Ontario (PRWEB) August 26, 2014

Spartan Bioscience today announced the appointment of Charudutt Shah as its Director of Business Development. Mr. Shah is responsible for expanding distribution of the Spartan RX CYP2C19 System in the United States and international markets. He is also responsible for new business opportunities and strategic initiatives for the company’s rapid sample-to-result genotyping platform.

Prior to joining Spartan, Mr. Shah was the Global Marketing Product Manager for Infectious Disease products at Luminex. He established Luminex’s international sales and distribution channels for molecular diagnostic products. Also, he was responsible for executing commercial strategies to achieve global sales targets. Prior to Luminex, Mr. Shah worked at Life Technologies and Toxikon Corporation.

“We are delighted that Charudutt Shah has joined our management team at Spartan Bioscience,” said Paul Lem, M.D., CEO of Spartan Bioscience. “Charudutt has deep experience in the molecular diagnostic industry and he will have an immediate impact on our business development efforts.”

About the Spartan RX CYP2C19 System
The Spartan RX CYP2C19 System is the first rapid pharmacogenetic test in medicine.(1) It identifies carriers of certain CYP2C19 genetic mutations in 1 hour. The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(2), including important drug classes such as antiplatelet therapies, beta blockers, antidepressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(3,4,5,6)

The Spartan RX CYP2C19 System has FDA 510(k) regulatory clearance for the United States, and CE IVD Mark regulatory approval for Europe and other countries recognizing the CE IVD Mark. For more information, please visit our website at: http://www.spartanbio.com/products/spartan-rx/overview/.

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing. Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.

1. Roberts JD et al. (2012). Lancet. 379:1705–11.
2. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
3. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
4. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
5. Oh IY et al. (2012). Heart. 98(2):139–44.
6. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12113718.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
2. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
3. Spartan Bioscience Receives FDA Clearance for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs
4. Spartan Bioscience Announces Medical Device Registration of Rapid CYP2C19 Testing System in Saudi Arabia
5. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
6. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
7. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
10. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):